Economics to boost antibiotics development
Considering the importance of antibiotics for our healthcare, the issue of a dwindling development pipeline must be addressed. This article outlines various economic suggestions.
Paying for patient expertise
Scientists in academic or other institutions use the unique insights patients provide to inform their research. Pharmaceutical companies oftentimes look for customer input primarily in late development stages. So far however, their main focus has been on […]
Justifying health insurance expenditure
It can be difficult for public health insurers to decide which medical interventions to cover. After all, it is the tax payers’ money that must be spent wisely and equitably across all patient groups.
Blue Steens in September 2019
Check out the monthly newsletter! It contains my last vlog, summarises Blue Steens’ latest posts and showcases some informative online content that I haven’t released elsewhere. Click to read >>>
Gender transition is in transition
Transgender health management has seen important advances in the recent past. Some notable remaining issues revolve around the standard of care and insurance coverage.
Blue Steens in August 2019
Check out the new monthly newsletter! It contains my last vlog, summarises Blue Steens’ latest posts and showcases some informative online content that I haven’t released elsewhere. Click to read >>>
Organ donation part 4/4 – Making transplant organs
If current organ donation systems don’t adapt, alternative solutions to the global organ shortage will hopefully emerge from biotechnology. Making organ donation work? Organ shortage is costly in terms of human lives, public expenditure and lost productivity […]